Vol.

No.

July 31, 2026Jul 31, 2026

DOWNLOAD THE PDF

Prediction markets now allow betting on clinical trial results, FDA decisions It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Cover Story

News Analysis

Prediction markets now allow betting on clinical trial results, FDA decisions

It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

By Sara Willa Ernst

Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v. Argentina World Cup final, and whether Trump will use the word “hippopotamus” in the month of July.

White House

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

By Jacquelyn Cobb

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

By Zachary S. Buchwald and Michael C. Lowe

Cancer History Project Free

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

By Sara Willa Ernst

Cancer Policy

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

HHS releases government-wide policy to prohibit gain-of-function research

WHO projects new cancer cases will rise to 35 million by 2050 globally

In Brief

Monica L. Baskin named director of VCU Massey CCC

Pamela Munster named inaugural associate director for early detection and interception research at Stanford

Kate Markey named Innovators Network Endowed Chair at Fred Hutch

ASTRO elects Beth Erickson president, announces other leadership roles

Mary Meyer, Scotty Cadet, Leena Gupta named to executive leadership roles at Curebound

UW Health | Carbone begins offering proton therapy

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

DNA atlas could power the next generation of AI drug discovery, Salk-led study finds

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

Moffitt-led team develops chemical approach to build safer precision medicines

Drugs & Targets

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

EMA CHMP recommends approval for biosimilar Denosumab Ascend and Nylaspeg, recommends against Tacquell

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 34 - September 18, 2026